Aug. 2 at 1:52 AM
$CMPX, unmet need, ODD/FTD
ORR: Clear win
18.0% vs 5.3%
More than a threefold improvement.
Statistically significant (p = 0.0228).
PFS: Strong win
4.7 vs 2.6 months.
HR = 0.44.
p < 0.0001.
A HR of 0.44 implies about a 56% reduction in the risk of progression or death, which is a large treatment effect.
OS: Difficult to interpret, but not clearly negative
54% of control patients crossed over to receive the experimental therapy.
That crossover substantially dilutes the ability to detect an overall survival difference in an intention-to-treat analysis.
Despite that, the crossover subset reportedly showed:
12.8 vs 6.1 months
HR = 0.54
p = 0.04
This is far much better trial draign and results than
$REPL. 50:50 on monday
Short intetest nearly 40%, and 15 days to cover, sufficient runway.
$KPTI equally confounded OS but runway is so small and risky
Next to watch
$SMMT
